摘要
实验证明国产米托蒽醌无论静脉、腹腔、皮下或灌胃给药,对小鼠S_(180)均有强的抑瘤作用,化疗指数为6.05。本品对小鼠P_(388)白血病、L_(1210)白血病、肝癌腹水型及lewis肺癌的抗瘤活性高于或相当于阿霉素。
China-synthesizedMitoxantrone(DHAQ)hasb been evaluatedfor antiturnor activity in experimentalmouse tumor systems. DHAQ showedpowerful tumor growth inhibition (TGI)activity by severel routes (iv ip sc pc) ofadministration in mice with S180 Whendoses from 0.41 to 1.8 mg/kg ip, the drugproduced 30.6-82.8% TGI and its chemot-herap eutic index was 6.05(LD50/ED50)on S180 mice The compound also producedsignificant increases in life span (ILS)andlong-term surviors when tested against theP388, L1210 leukemia and Hep A. The optimaltreatment regimens resulted in a>200% ILSwith 42-66% 90-day survivors inmice withp_(338)Leukemia, a>327% ILS with 29% 90-day survivors in mice with L1210 leukemia,a 191% ILS with 30% 90-day survivors inmice with Hep A. The compound showedeffective antitumor activity and produceda 62% TGI in mice with Lewis lung ca-rcinoma. The above-mentioned results weresuperior or similar to the effects of ADR.
出处
《华西药学杂志》
CAS
CSCD
北大核心
1989年第2期79-81,共3页
West China Journal of Pharmaceutical Sciences
关键词
米托蒽醌
抗癌药
实验治疗
小鼠
Mitoxantrone
Anticancer drug
Experimental therapy of tumor Chemo-therapeutic index
